✨ Free AI Report
Acelyrin Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Acelyrin Inc.
Research Preview

Acelyrin Inc.: Business Overview, Financials & Competitive Analysis

Acelyrin was a late-stage clinical biopharma company focused on immune-mediated diseases that completed a merger with Alumis in May 2025, with ACELYRIN stock ceasing to trade on NASDAQ. The company focused on accelera...

Analyst-debate audio for Acelyrin Inc.

AskCyborg analysts argue the bull and bear cases for Acelyrin Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Acelyrin Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
5/ 10Mixed

Cyborg Score thesis

Acelyrin's immunology assets are now part of Alumis, blending precision analytics with late-stage clinical programs in...

Read the full analyst-debate transcript →
Industry Clinical-stage immunology therapeutics
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: July 13, 2026
AI-Verified Research
30+ Page Report

Get the Latest Acelyrin Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Acelyrin Inc. Overview

Pro stress-test →

Acelyrin was a late-stage clinical biopharma company focused on immune-mediated diseases that completed a merger with Alumis in May 2025, with ACELYRIN stock ceasing to trade on NASDAQ. The company focused on accelerating the development and commercialization of medicine, primarily in the field of immunology.

Strategic Profile

Pro stress-test →

Acelyrin's pipeline was led by izokibep, a small therapeutic protein inhibitor of interleukin-17A (IL-17A) designed to overcome the limitations of monoclonal antibodies. Through the merger with Alumis, the combined company gained financial flexibility and runway to advance an expanded late-stage pipeline, now including lonigutamab.

Competitive Landscape

Pro stress-test →

As of July 2026, Acelyrin no longer operates as an independent company. However, its former pipeline focused on IL-17A inhibition and thyroid eye disease treatment competed with companies developing targeted immunology therapies.

Industry Context

Acelyrin Inc. operates in Clinical-stage immunology therapeutics.

Key facts

Founded: 2020 · Headquarters: Agoura Hills, CA, US · Employees: N/A · Revenue: N/A · Market cap: N/A (Acquired)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Acelyrin Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Acelyrin Inc. has a new material development →

Compare Acelyrin Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Acelyrin Inc. operates in Clinical-stage immunology therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical-stage immunology therapeutics research →
NEW · MCP server

Ask your AI assistant about Acelyrin Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Acelyrin Inc. and its top competitor on Cyborg Score”
“What did Acelyrin Inc. do this quarter?”
“Is Acelyrin Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Acelyrin Inc. do?+
Acelyrin was a late-stage clinical biopharma company focused on immune-mediated diseases that completed a merger with Alumis in May 2025, with ACELYRIN stock ceasing to trade on NASDAQ. The company focused on accelera...
What is Acelyrin Inc.'s Cyborg Score?+
Acelyrin Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Acelyrin Inc.'s main competitors?+
The full competitive landscape for Acelyrin Inc. is in the AskCyborg report.
How can I get the full Acelyrin Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Acelyrin Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Acelyrin Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9GELEX Group Joint Stock Company9TTM Technologies, Inc.9Insulet Corporation9Marathon Petroleum Corporation9Seagate Technology Holdings plc9Howmet Aerospace Inc.9Investor AB9Micron Technology, Inc.9Taiwan Semiconductor Manufacturing Company Limited9NVIDIA Corporation8NIO Inc.8Seanergy Maritime Holdings Corp.8Grupo Aeroméxico, S.A.B. de C.V.8Gulf Medical Projects Company8Interloop Limited8Kyverna Therapeutics, Inc.8Tatton Asset Management Plc8Invictus Investment Company PLC